title: Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia.
authors.affiliation: Launceston General Hospital, Tasmania, Australia.
authors.forename: Alhossain
authors.initials: A
authors.lastname: Khalafallah
authors.forename: Terry
authors.initials: T
authors.lastname: Brain